Horizon Discovery plcの利益マージン
Horizon Discovery plcの利益マージンは何ですか。
Horizon Discovery Group plcの利益マージンは-7.91%です。
利益マージンの定義は何ですか。
利益マージンは、収益性の尺度であり、収益の割合として純利益を求めることによって計算されます。
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
LSEのセクタHealth Careにおける利益マージンの企業と比べるHorizon Discovery plc
Horizon Discovery plcは何をしますか。
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Horizon Discovery plcと類似の利益マージン
- Conduent Incの利益マージンは-7.95%です。
- Fortis Malar Hospitalsの利益マージンは-7.95%です。
- AT&Tの利益マージンは-7.94%です。
- Vedantaの利益マージンは-7.94%です。
- SED Internationalの利益マージンは-7.92%です。
- medical columbus AGの利益マージンは-7.91%です。
- Horizon Discovery plcの利益マージンは-7.91%です。
- National Express Plcの利益マージンは-7.90%です。
- Antioquia Goldの利益マージンは-7.89%です。
- BaWang International ()の利益マージンは-7.89%です。
- The Alumasc plcの利益マージンは-7.88%です。
- Kinetic Engineeringの利益マージンは-7.88%です。
- American Public Education Incの利益マージンは-7.87%です。